Just how big is AAD’s annual gathering? Dr. Muneeb Shah, a dermatologist speaking during a global press event for CeraVe, likened it to the “Super Bowl for dermatologists.”
This is the first time the meeting is being held in Boston. It will conclude on March 29.
Here’s a quick rundown of some of the news from leading skin care companies operating in OTC, in-office and prescription treatment arena as well as other developments related to the field of dermatology.
New Rx Acne Care from Galderma
Galderma announced the US launch of Twyneo Cream, a tretinoin and benzoyl peroxide combination to treat facial acne available by prescription. It is said to be the first and only 0.1% tretinoin and 3% benzoyl peroxide (BPO) 2-in-1 combination proven to rapidly treat moderate to severe facial acne. Patented microencapsulation technology unites two ingredients that have not been previously combined and enables their controlled release to deliver visible results in as little as two weeks. In clinical trials, some people saw results in as little as two weeks of using Twyneo Cream, and their skin continued to clear over time These studies demonstrated a 25% decrease in pimples at two weeks and a 58–66% decrease at 12 weeks; with 27–41% of people achieving clear or almost clear skin by the end of the trial. More than half of people who used Twyneo Cream were satisfied at two weeks and by 12 weeks of treatment, 8 in 10 persons were satisfied with their results with 9 in 10 people staying on treatment until the end of the trial. The cream was well tolerated and side effects were mild to moderate and decreased over time, said Galderma. The most common side effects occurring in >2% of persons using the cream were application site pain, dryness, erythema (redness and exfoliation. It will be commercially available in the spring according to the company.
Galderma also showcased its latest approved and investigational product updates. Topics/presentations/abstracts included:
• “Efficacy, Tolerability, and Cosmetic Acceptability of an Acne Regimen Specifically Designed for Sensitive Skin”
• “Dual Study: Trifarotene Plus Doxycycline Has Proven Efficacy and Safety in Severe Acne Vulgaris”
• “An In-vitro Evaluation of a Niacinamide-Panthenol-Glycerin Complex on Skin Barrier Function, Hydration, and Neuro-Inflammation
• :Association of adult atopic dermatitis severity with decreased physical activity: A cross-sectional study”
Additionally, Galderma particicpated in product theaters including:
• Cetapil Sensitive Skin—Advancing Sensitive Skin: Diagnosis, Morphological Traits and Epidemiology
• Cetaphil Pediatric—Paediatric Atopic Dermatitis: Current Developments
• A Neuroimmune Perspective on Itch and Skin Inflammation in Atopic Dermatitis and Prurigo Nodularis. (Prurigo nodularis is a chronic inflammatory skin disease in which there is extreme itch and a symmetrically distributed rash appears most commonly on the arms, legs, the upper back and/or the abdomen. The itch can be severe that it often interferes with sleep and psychological wellbeing.)
Alma, a company active in energy-based medical and aesthetic solutions industry, used AAD to announce the commercial launch of CBD+ Professional Skincare Solution, a professional solution that the company says combines the scientific benefits of full-spectrum CBD, with clinically proven cosmetic ingredients to visibly rebalance the skin back to a natural, healthy state. The range features 10 products and represents the first commercial brand and expansion into the US market for Alma under its parent company, Sisram Medical. The company also unveiled to US market, Alma TED, an ultrasound-based system with a propriety tip engineered with Impact Delivery that offers a non-invasive, non-traumatic option to address the market’s growing hair loss concerns.
Young Pharmaceuticals has formed an exclusive North America distribution partnership with Lactobio to offer BAK Probiotic Skincare. Copenhagen-based Lactobio’s BAK Probiotic Skincare will be available in the US marketplace through plastic surgeons and dermatologists. The products come from years of research based on the latest science of the microbiome, according to the company.
Skin Cancer Education and Diagnosis
Announced at AAD, Mohs-Facts.org is a new consumer education website that developer says fills gaps in patient education about mohs surgery for common basal and squamous cell skin cancers. Developed by SkinCure Oncology using health literacy guidelines, it offers a complete and balanced view of Mohs surgery. Information and images explain how the surgery is performed, and what patients can do before and after surgery to improve outcomes. Site visitors will learn about the wounds and scars often left by Mohs, and steps they can take to promote healing and avoid complications. The site provides advice on how to partner with one’s doctor, with tips on discussing whether Mohs is the right treatment, and advice on the availability of FDA-cleared treatment options that do not involve surgery.
DermTech, a genomics company active in dermatology, has developed a melanoma test that uses a smart sticker to collect DNA from the surface of a patient’s skin to test for the earliest markers of melanoma with what it contends is a less than 1% probability of missing melanoma. The company is taking part in the AAD Spot Skin Cancer campaign, where every visit to the team at booth #3027 will generate a $100 donation.
AbbieVie and Allergan Aesthetics spotlighted a novel hydrating serum and shared results from a multicenter and randomized controlled study evaluating the safety and effectiveness of hyaluronic acid (HA) injectable gel for restoring jawline definition as well as data on the effectiveness and safety of onabotulinumtoxinA for the treatment of masseter muscle prominence. Abstracts at AAD 2022 include those addressing atopic dermatitis, psoriasis, psoriatic arthritis and aesthetics. These included: “Improvement in Skin Quality with a Cosmetic Hydrating Serum Delivered via Diamond Tip Microdermabrasion Combined with Topical Daily Serum” and “Mechanism for Improvement in the Appearance of Skin Laxity Resulting from a Single Treatment with Acoustic Subcision: Induction of New Collagen (Type III) and Elastin.”
A New Franchise at RoC
RoC Skincare, as previously reported by Happi, used AAD to debut a new franchise under the Derm Correxion banner. The premier product is RoC Derm Correxion Fill + Treat Serum.
Updates from J&J Consumer Health
Johnson & Johnson Consumer Health released news around vitamin C, oats, skin aging and sun care as reported by Happi on Friday.
Body Skin Health
As part of its new “Skincare You Want to Share”campaign, CeraVe released new survey findings that incorpoated 54 dermatologists from 23 different countries. According to the survey, 90% of dermatologists surveyed said applying a moisturizer to the body daily is important to very important for overall skin health and 87% believe moisturizing the body is as important or more important as facial moisturizing. These findings emphasize that the importance of body moisturizing for achieving healthy skin is universally recognized among dermatologists. However, dermatologist recommendations are not always reflected in patient behavior, according to the brand. The survey found that more than one-third (35%) of dermatologists surveyed believe that their patients often neglect all body parts except the face. The most often neglected body parts, according to the dermatologists surveyed, were legs and feet (59%), followed by the neck (37%) and arms and elbows (35%).
DEI & URiM
Launched by the American Academy of Dermatology (AAD) in collaboration with Johnson & Johnson Consumer Health and the Janssen Pharmaceutical Companies of Johnson & Johnson, Pathways: Inclusivity in Dermatology is designed to increase the number of practicing dermatologists who are underrepresented minorities in medicine (URiM). Through scholarship offerings, skills workshops, mentorship programs, and leadership training, Pathways aims to increase the number of dermatology residents from Black, Latino, and Indigenous communities from approximately 100 residents to 250, or by over 50%, by 2027.
VisualDx, a diagnostic clinical decision support system used at US medical schools and hospitals and clinics, used AAD to herald and celebrate the one-year anniversary of Project IMPACT(Improving Medicine’s Power to Address Care and Treatment), a global effort to reduce disparities in medicine, highlight ways to bridge gaps of knowledge, and improve healthcare outcomes for patients of color. Since launching in last March, Project IMPACT has reached 1.5 million healthcare professionals and students globally and has garnered early notoriety and momentum with support from inaugural members like the Skin of Color Society (SOCS) and New England Journal of Medicine (NEJM) Group. Project IMPACT now boasts eight collaborating organizations, including the AAD, American Medical Women’s Association, and the Student National Medical Association.
Dark skin is significantly underrepresented in medical literature and curricula, comprising an average of just 4.5% of images in medical textbooks. Consequently, clinicians of all licensures and specialties are often insufficiently trained to recognize disease patterns in patients of color. To confront this issue, VisualDx, SOCS, and NEJM Group organized a webinar series in 2020 to educate providers on structural racism in medicine, disease patterns in dark skin types, and culturally competent care. Following the positive response from more than 32,000 registrants representing nearly 100 countries, VisualDx launched Project IMPACT to raise awareness and drive adoption of educational and clinical resources and solutions that bolster clinicians’ ability to accurately diagnose disease in black and brown skin and improve health equity.
“Project IMPACT was borne out of the concept that healthcare providers who diagnose and treat dermatologic conditions must be able to recognize disease in all skin colors,” said Nada Elbuluk, MD, MSc, FAAD, a board-certified dermatologist and Director of Clinical Impact at VisualDx. “I am excited to see how far Project IMPACT has spread and what a positive influence it has had on practicing clinicians, medical students, and patients alike. At Project IMPACT and at VisualDx, we are trying address healthcare disparities and work toward equity and better outcomes for all, and by rallying people around a singular effort, we can do so. For Project IMPACT’s second year, our goal is to add even more collaborators and continue to spread the message of inclusion.”
The next AAD Annual Meeting will be held March 17-21, 2023 in New Orleans.